Vida Ventures related stories
All articles and analysis
Locanabio pulls in $100m Series BLocanabio Inc, an RNA-targeting gene therapy company, has raised $100 million in Series B financing.
Breakthrough Properties racks up over $1bn for life science property fundBreakthrough Properties has raised over $1 billion for its life science property fund.
Praxis Precision Medicines starts trading on NASDAQCambridge, Massachusetts-based Praxis Precision Medicines, a developer of treatments for central nervous system disorders, has raised about $190 million for its IPO after pricing 10 million shares at $19 per share.
A2 Biotherapeutics scores $71.5m Series BAgoura Hills, California-based A2 Biotherapeutics, a developer of cell therapies for solid tumor cancer patients, has raised $71.5 million in Series B financing.
- Praxis Precision Medicines attracts $110m
Cambridge, Massachusetts-based Praxis Precision Medicines, a biopharmaceutical company, has raised $110 million in Series C1 financing.
Gilead Sciences to acquires stake in VC-backed PionyrGilead Sciences Inc has agreed to acquire 49.9 percent stake in Pionyr Immunotherapeutics Inc, a developer of cancer immunotherapies.
- Kyverna Therapeutics scores $25 mln Series A
Berkeley, California-based Kyverna Therapeutics, a cell therapy company, has secured $25 million in Series A funding.
- PACT Pharma lands $75 mln Series C
South San Francisco-based PACT Pharma, a clinical-stage company, has raised $75 million in Series C financing.
- A2 Biotherapeutics takes in $57 mln Series A
A2 Biotherapeutics, a developer of cell therapies for cancer patients, has raised $57 million in Series A funding. The investors included The Column Group, Vida Ventures, Samsara BioCapital and Nextech Invest.
Toncheva promoted at USVP, Investor bails on Vision Fund, and a monthly recap of other VCs on the MoveA compilation of personnel moves from the previous four weeks at various firms, including USVP, Next Ventures and SoftBank